Oruka Therapeutics (ORKA) Asset Writedowns and Impairment (2024)
Oruka Therapeutics' (ORKA) quarterly Asset Writedowns and Impairment came in at $1.5 million in Q3 2024, up 73150.0% quarter-over-quarter from $2000.0 in Q2 2024.
Oruka Therapeutics (ORKA) Asset Writedowns and Impairment (2024) Analysis & Trends
Oruka Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $1.5 million for Q3 2024.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $1.5 million in Q3 2024; TTM through Dec 2024 was $1.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $1.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment grew to $1.5 million in Q3 2024 per ORKA's latest filing, from $2000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.5 million in Q3 2024 and bottomed at $1000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 952.72 Mn | 121.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |